These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427 [TBL] [Abstract][Full Text] [Related]
50. Investigation of receptor radionuclide therapy with Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927 [TBL] [Abstract][Full Text] [Related]
51. PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center. Puranik AD; Dev ID; Rangarajan V; Kulkarni S; Shetty N; Gala K; Sahu A; Bhattacharya K; Dasgupta A; Chatterjee A; Gupta T; Sridhar E; Sahay A; Shetty P; Singh V; Moiyadi A; Menon N; Purandare NC; Agrawal A; Shah S; Choudhury S; Ghosh S; Jha AK Neurol India; 2024 Mar; 72(2):278-284. PubMed ID: 38691470 [TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature. Tang CYL; Chua WM; Huang HL; Lam WW; Loh LM; Tai D; Ong SYK; Yan SX; Loke KSH; Ng DC; Tham WY J Neuroendocrinol; 2023 Dec; 35(12):e13349. PubMed ID: 37937484 [TBL] [Abstract][Full Text] [Related]
53. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066 [TBL] [Abstract][Full Text] [Related]
54. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750 [TBL] [Abstract][Full Text] [Related]
55. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242 [TBL] [Abstract][Full Text] [Related]
56. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Severi S; Nanni O; Bodei L; Sansovini M; Ianniello A; Nicoletti S; Scarpi E; Matteucci F; Gilardi L; Paganelli G Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):881-8. PubMed ID: 23443937 [TBL] [Abstract][Full Text] [Related]
57. Safety and outcomes of Lin E; Chen T; Little A; Holliday L; Roach P; Butler P; Hosking E; Bailey E; Elison B; Currow D Intern Med J; 2019 Oct; 49(10):1268-1277. PubMed ID: 31062490 [TBL] [Abstract][Full Text] [Related]
58. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors. Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941 [TBL] [Abstract][Full Text] [Related]
59. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198 [TBL] [Abstract][Full Text] [Related]
60. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]